Eli Lilly Stock: Why There’s Still A Lot To Like In 2025 Despite Guidance Cut
There’s still a lot to like about Eli Lilly (LLY) stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its fourth-quarter sales guidance by 5%. ↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy? Eli Lilly now expects $13.5 billion in fourth-quarter sales,…